A Silver Lining Amid a Global Health Crisis
For years, viral hepatitis has been the quiet epidemic — overshadowed by HIV, malaria, and tuberculosis in global health campaigns. But a new World Health Organization report, released this week at the World Hepatitis Summit, offers a rare dose of optimism: infections are falling, childhood cases are shrinking, and more countries than ever are proving that elimination is not a pipe dream. Yet beneath this hopeful veneer lies a stark reality: more than 1.3 million people died from hepatitis B and C in 2024 alone, and fresh infections continue to accumulate at a staggering rate of 4,900 per day. The disease remains a massive, largely unaddressed killer — and the clock is ticking on a 2030 deadline that many nations are at risk of missing.
Why So Many Are Still Dying
The numbers tell a story of stark inequity. In 2024, the WHO estimates that 287 million people were living with chronic hepatitis B or C. Yet fewer than 5% of those with hepatitis B received treatment, and only 20% of hepatitis C patients have been cured since 2015 — despite the availability of a short-course therapy that works in more than 95% of cases. The disconnect between medical capability and real-world delivery is staggering. Most deaths stem from liver cirrhosis or liver cancer — diseases that are almost entirely preventable if infections are caught and managed early.
Why are so many slipping through the cracks? Stigma, weak health systems, and unequal access to care are the main culprits. The WHO African Region, for example, accounts for 68% of new hepatitis B infections — but only 17% of newborns there receive the birth-dose vaccine that could prevent the disease entirely. In many parts of the world, people who inject drugs make up 44% of new hepatitis C infections, yet harm reduction services remain woefully underfunded or nonexistent.
The Countries That Are Getting It Right
Not all news is grim. Several countries — notably Egypt, Georgia, Rwanda, and the United Kingdom — have demonstrated that with sustained political commitment and domestic financing, elimination is achievable. Egypt, in particular, launched a nationwide testing and treatment campaign that has slashed hepatitis C prevalence dramatically. Their success shows that the tools we have work; the real challenge is deploying them at scale and reaching the most vulnerable populations.
What Needs to Change — Fast
The current trajectory will not meet the 2030 elimination targets, and the WHO report is blunt about what must happen next. Among the priority actions:
- Scale up treatment for chronic hepatitis B, especially in Africa and the Western Pacific, where most deaths occur.
- Expand access to hepatitis C cures, particularly in the Eastern Mediterranean region.
- Boost birth-dose vaccination coverage and antiviral prophylaxis to prevent mother-to-child transmission — a simple, proven intervention that remains underused in many high-burden countries.
- Strengthen harm reduction services for people who inject drugs, who represent a growing share of new infections.
Ten countries — Bangladesh, China, Ethiopia, Ghana, India, Indonesia, Nigeria, the Philippines, South Africa, and Vietnam — account for 69% of hepatitis B deaths globally. That means targeted investment in just a handful of nations could yield enormous progress.
An Uncomfortable Truth: We Are Choosing Not to Act
From a journalistic perspective, what stands out most about this report is not its data — but its implication that the world has the means to end hepatitis as a major public health threat, yet is choosing not to. The vaccines, the cures, and the diagnostic tools all exist. The cost is relatively modest compared to the burden of chronic liver disease. What is missing is political will, consistent funding, and a health-system focus on prevention rather than crisis management.
For readers, the takeaway is personal: hepatitis remains a largely silent threat that can live in the body for decades before causing fatal liver damage. If you are in a high-risk group — or simply haven’t been tested — the report is a reminder that a simple blood test could save your life. For policymakers, the message is even more urgent: every day of inaction means thousands of new infections and hundreds of preventable deaths. The tools are ready. The question is whether the world is ready to use them.
The Bottom Line
Progress is real, but it is uneven and far too slow. As WHO Director-General Dr. Tedros Adhanom Ghebreyesus put it, eliminating hepatitis is not a pipedream — it’s possible. But only if countries act as though they believe it.
